TH07 Hair Regrowth Trial: Key Findings Explained in Plain Language
A combination topical formula (minoxidil + finasteride + latanoprost + ketoconazole) produced results 4x better than minoxidil alone in a Phase 2 trial.
Study overview
Conducted by
Multi-center dermatology research consortium
Patients
Approximately 450 men with androgenetic alopecia (male pattern baldness)
Duration
12 months
Published in
Frontiers in Medicine (meta-analysis of combination therapy trials)
Year
2022
Key findings
82% achieved moderate to dense hair regrowth at 6 months
Using blinded investigator assessments and global photography, 82% of patients on the combination formula showed clinically meaningful regrowth by the 6-month mark.
94.1% improvement rate at 12 months
By one year, nearly all patients on combination therapy showed measurable improvement in hair density and coverage.
4x more effective than minoxidil monotherapy
The meta-analysis across 450 patients showed the combination approach significantly outperformed minoxidil alone in both hair count and investigator-assessed density.
Topical finasteride reduced scalp DHT without systemic absorption
The 0.3% topical finasteride concentration blocked DHT at the follicle while maintaining blood finasteride levels far below the oral 1mg dose.
What this means for you
Single-compound approaches to hair loss are leaving results on the table. By attacking DHT (finasteride), blood flow (minoxidil), growth cycle length (latanoprost), and inflammation (ketoconazole) simultaneously, the combination formula produces dramatically better outcomes. This is why LYV uses a 4-compound topical rather than minoxidil alone.
Limitations
The 450-patient figure comes from meta-analysis across multiple studies, not a single large trial. Most participants were men; data in women is more limited. The 12-month timeframe may not reflect maximum potential results, as hair growth continues beyond 12 months.
See if this compound is right for your goals
Take a 2-minute quiz. Get a personalized protocol.